10/561414

MP12 Rec'd PCT/PTO 19 DEC 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Borthwick, et al.

International App. No.:

PCT/EP2004/006603

Disclosure Statement under § 1.97(c) (\$240.00).

Group Art Unit:

International Filing Date: June 17, 2004

Examiner:

For:

PYRROLIDINE - 2- ONES AS FACTOR XA INHIBITORS

Commissioner for Patents Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

	[] Co [X] A PC Re	pies of the references are enclosed pies of the references were submitted in parent application Serial No (37 CFR 1.98(d)) copy of the International Search Report which issued on International Application No. CT/EP2004/006603 is submitted herewith. All of the publications cited in the International Search port are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied the U.S. Patent Office by the International Bureau.
A.	[X]	The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).
	OR []	The Information Disclosure Statement submitted herewith is being filed before the mailing
		of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).
В.	[]	The Information Disclosure Statement transmitted herewith is being filed after three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but before the mailing date of either: (1) a final action under § 1.113 or (2) a notice of allowance under § 1.311, nichever occurs first.
	[]	Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
	[]	Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information

10/561414 MP12Rec'd PCT/PTO 19 DEC 2005

C.	[]	The Information Disclosure Statement transmitted herewith is being filed after a final action up 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.						
	In accordance with the requirements of 37 CFR 1.97(d):							
]	Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.						
	[]	Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii).						
	[]	The petition fee set forth in § 1.17(i)(1) (\$130.00) is submitted herewith.						
[X []	-	charge any required fees to Deposit Account No.07-1392. icate copy of this paper is attached.						

Respectfully Submitted,

Amy H. Fix

Attorney for Appliant Registration No. 42,616

Date: 16 Dec. 2005

GlaxoSmithKline

Corporate Intellectual Property 5 Moore Drive, P.O. Box 13398 Research Triangle Park, NC 27709-3398

Telephone: (919) 483-8911 Facsimile: (919) 483-7988

IAP12 Rec'd PCT/PTO 19 DEC 2005

Page 1 of 1

FORM PT INFORM		9 N DISCLOSURE	STATEMEN	Γ	ATTORNEY DOCKET NO. PB60627USW APPLICANT Borthwick et al.		INTERNATIONAL APP. NO. PCT/EP2004/006603	
				INTERNATIONAL FILING DATE 6/17/04		GROUP		
			U.S. P.	ATENT D	OCUMENTS_			
Examiner Initials		Patent Number	Issue Date		Name	Class	Subclass	Filing Date If Appropriate
	1	6,034,093	3/7/00	Ewing et		–		
	2	2002/183324	12/5/03	Jacobson				
	3	6,348,600	2/19/02	Ono et al	•			
				<u> </u>				
				ontinue on		10		
		T =	1	N PATEN'	T DOCUMENT	18		Translation
		Document Number	Publication Date		Country	Class	Subclass	Yes No
-	4	03/053925	7/3/03	PCT				ļ
	5	03/043981	5/30/03	PCT				
	6	2004/026826	4/1/04	PCT				ļ
	7	2002/002519	1/10/02	PCT				
	8	92/10476	6/25/92	PCT				<u> </u>
	9	97/43257	11/20/97	PCT				
	10	2002/080853	10/17/02	PCT				ļ
	-		-				-	
								
	.l			ontinue on	nage	<u> </u>		!
	07	THER DOCUME				Date Page Ni	ımber. Etc.)	
	T .		arvis (includi	ig riuthor,	, ritie, oournar	Dute, Luge 111		
	1							
	 							
								· · · · · ·
			111					
	 				· · · · · · · · ·			
	-							
	+							
<u> </u>				ontinua a=	n ogo			
EXAMINI	ER			Continue on	page	DATE	CONSIDERED)
		itial if citation co						